These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

889 related articles for article (PubMed ID: 28601382)

  • 81. Is SLN Biopsy Alone Safe in SLN Positive Breast Cancer Patients?
    van la Parra RF; de Wilt JH; Mol SJ; Mulder AH; de Roos WK; Bosscha K
    Breast J; 2015; 21(6):621-6. PubMed ID: 26391102
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.
    Hieken TJ; Boughey JC; Jones KN; Shah SS; Glazebrook KN
    Ann Surg Oncol; 2013 Oct; 20(10):3199-204. PubMed ID: 23846781
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Positive versus negative sentinel nodes in early breast cancer patients: axillary or loco-regional relapse and survival. A study spanning 2000-2012.
    García Fernández A; Chabrera C; García Font M; Fraile M; Lain JM; Barco I; González C; Gónzalez S; Reñe A; Veloso E; Cassadó J; Pessarrodona A; Giménez N
    Breast; 2013 Oct; 22(5):902-7. PubMed ID: 23684000
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Axillary lymph node recurrence following wire-directed sentinel lymph node dissection for breast cancer patients with biopsy-proven axillary metastases prior to neoadjuvant chemotherapy at a safety net medical center.
    Sargent RE; Siegel E; Ito F; Kramme K; Kraft E; Hendrix V; Carr AA; Nelson ME; Bian SX; Jayachandran P; Sener SF
    J Surg Oncol; 2023 Jul; 128(1):9-15. PubMed ID: 36933187
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Is it always necessary to perform an axillary lymph node dissection after neoadjuvant chemotherapy for breast cancer?
    Osorio-Silla I; Gómez Valdazo A; Sánchez Méndez JI; York E; Díaz-Almirón M; Gómez Ramírez J; Rivas Fidalgo S; Oliver JM; Álvarez CM; Hardisson D; Díaz Miguel M; Lobo F; Díaz Domínguez J
    Ann R Coll Surg Engl; 2019 Mar; 101(3):186-192. PubMed ID: 30421628
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer.
    Julian TB; Dusi D; Wolmark N
    Am J Surg; 2002 Oct; 184(4):315-7. PubMed ID: 12383891
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Neo-adjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer.
    Shi ZQ; Qiu PF; Liu YB; Cong BB; Zhao T; Chen P; Wang CJ; Zhang ZP; Sun X; Wang YS
    Breast J; 2019 Nov; 25(6):1154-1159. PubMed ID: 31332886
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Improving the Success Rate of Repeat Sentinel Node Biopsy in Recurrent Breast Cancer.
    Vugts G; Maaskant-Braat AJ; Voogd AC; van Riet YE; Roumen RM; Luiten EJ; Rutgers EJ; Wyndaele D; Rutten HJ; Nieuwenhuijzen GA
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S529-35. PubMed ID: 26259754
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [A new perspective on axillary dissection in situations of metastatic sentinel node].
    Zedníková I; Ňaršanská A; Hes O; Metelková A; Fiala O; Svoboda T
    Rozhl Chir; 2017; 96(8):346-352. PubMed ID: 29058925
    [TBL] [Abstract][Full Text] [Related]  

  • 90. A nonrandomized follow-up comparison between standard axillary node dissection and sentinel node biopsy in breast cancer.
    Konstantiniuk P; Schrenk P; Reitsamer R; Koeberle-Wuehrer R; Tausch C; Roka S; Riedl O; Poestlberger S; Hecke D; Janauer M; Haid A
    Breast; 2007 Oct; 16(5):520-6. PubMed ID: 17566737
    [TBL] [Abstract][Full Text] [Related]  

  • 91. "Axillary recurrences after sentinel lymph node biopsy: a multicentre analysis and follow-up of sentinel lymph node negative breast cancer patients".
    van Wely BJ; van den Wildenberg FJ; Gobardhan P; van Dalen T; Borel Rinkes IH; Theunissen EB; Wijsman JH; Ernst M; van der Pol CC; Madsen EV; Vles WJ; Wauters CA; de Wilt JH; Strobbe LJ
    Eur J Surg Oncol; 2012 Oct; 38(10):925-31. PubMed ID: 22633152
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Advantages of preoperative localization and surgical resection of metastatic axillary lymph nodes using magnetic seeds after neoadjuvant chemotherapy in breast cancer.
    Mariscal Martínez A; Vives Roselló I; Salazar Gómez A; Catanese A; Pérez Molina M; Solà Suarez M; Pascual Miguel I; Blay Aulina L; Ríos Gozálvez C; Julián Ibáñez JF; Rodríguez Martínez P; Martínez Román S; Margelí Vila M; Luna Tomás MA
    Surg Oncol; 2021 Mar; 36():28-33. PubMed ID: 33285433
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Response rate to neoadjuvant chemotherapy measured on imaging predicts early recurrence and death in breast cancer patients with lymph node involvements.
    Nagashima T; Sakakibara M; Kadowaki M; Suzuki TH; Yokomizo J; Ohki Y; Miyoshi T; Kazama T; Nakatani Y; Miyazaki M
    Acta Radiol; 2011 Apr; 52(3):241-6. PubMed ID: 21498357
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Sentinel node mapping performed before preoperative chemotherapy may avoid axillary dissection in breast cancer patients with negative or micrometastatic sentinel nodes.
    Schrenk P; Tausch C; Wölfl S; Bogner S; Fridrik M; Wayand W
    Am J Surg; 2008 Aug; 196(2):176-83. PubMed ID: 18513692
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Use of ultrasound and MRI to stage the axilla for breast cancer before and after neoadjuvant chemotherapy prior to targeted sentinel lymphadenectomy.
    Brabender D; Ballard A; Kim S; Hovanessian-Larsen L; Sener SF
    Breast Cancer Res Treat; 2024 Aug; 206(3):595-602. PubMed ID: 38700572
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Assessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype.
    Maeshima Y; Sakai T; Ogiya A; Takahashi Y; Miyagi Y; Kokubu Y; Osako T; Ito Y; Takahashi S; Ohno S; Ueno T
    Sci Rep; 2021 May; 11(1):10858. PubMed ID: 34035335
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Clinical Impact of Fine Needle Aspiration Cytology on Sentinel Node Biopsy after Preoperative Chemotherapy for Core Needle Biopsy-Proven Metastatic Lymph Nodes.
    Nakamura R; Hayama S; Yoshimura S; Itami M; Araki A; Odaka A; Yamamoto N
    Acta Cytol; 2023; 67(4):378-387. PubMed ID: 36796341
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Impact of neoadjuvant chemotherapy on axillary nodal involvement in patients with clinically node negative triple negative breast cancer.
    Connor CS; Kimler BF; Mammen JM; McGinness MK; Wagner JL; Alsop SM; Ward C; Fabian CJ; Khan QJ; Sharma P
    J Surg Oncol; 2015 Feb; 111(2):198-202. PubMed ID: 25266871
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast.
    Schwartz GF; Tannebaum JE; Jernigan AM; Palazzo JP
    Cancer; 2010 Mar; 116(5):1243-51. PubMed ID: 20087958
    [TBL] [Abstract][Full Text] [Related]  

  • 100. A Novel Less-invasive Approach for Axillary Staging After Neoadjuvant Chemotherapy in Patients With Axillary Node-positive Breast Cancer by Combining Radioactive Iodine Seed Localization in the Axilla With the Sentinel Node Procedure (RISAS): A Dutch Prospective Multicenter Validation Study.
    van Nijnatten TJA; Simons JM; Smidt ML; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef K; Koppert LB; Luiten EJT
    Clin Breast Cancer; 2017 Aug; 17(5):399-402. PubMed ID: 28487053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.